Content about Advisory board

August 21, 2012
Former Walmart exec David Hoodis joins Natural Insight's advisory board

Former Walmart executive David Hoodis has joined the corporate advisory board of Natural Insight, a private retail technology company engaged in workforce management.

STERLING, Va. — Former Walmart executive David Hoodis has joined the corporate advisory board of Natural Insight, a private retail technology company engaged in workforce management.

“We feel privileged to have access to David’s respected experience in workforce innovation. His success with numerous leading retailers brings us an added perspective that enables us to stay even further ahead of market need,” stated Stefan Midford, president and CEO of Natural Insight in making the announcement.

July 11, 2012
Orabrush forms new advisory board

Tongue cleaner manufacturer Orabrush has added David Kelley, founder and chairman of the global innovation and design firm IDEO, and Mikel Chertudi, senior director of global media and demand marketing at Adobe, to its recently formed advisory board.

PROVO, Utah — Tongue cleaner manufacturer Orabrush has added David Kelley, founder and chairman of the global innovation and design firm IDEO, and Mikel Chertudi, senior director of global media and demand marketing at Adobe, to its recently formed advisory board.

As advisory board members, Kelley and Chertudi will lend their expertise to the Orabrush team as the company builds on the momentum created by its digital marketing strategy on YouTube.

August 30, 2011
Craig Eagle joins corporate advisory board at Provectus

The VP strategic alliances and partnerships for Pfizer's oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.

KNOXVILLE, Tenn. — The VP strategic alliances and partnerships for Pfizer's oncology division has joined the corporate advisory board at a development-stage oncology and dermatology biopharmaceutical company.

Provectus Pharmaceuticals said that the company will benefit from Craig Eagle's "vast experience in drug development" as the drug maker seeks to commercialize its cancer and dermatological therapies.